{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:21:54Z","timestamp":1785280914650,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2013,8,6]],"date-time":"2013-08-06T00:00:00Z","timestamp":1375747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,8,6]],"date-time":"2013-08-06T00:00:00Z","timestamp":1375747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1007\/s40264-013-0091-1","type":"journal-article","created":{"date-parts":[[2013,8,8]],"date-time":"2013-08-08T17:39:39Z","timestamp":1375983579000},"page":"1087-1096","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Adverse Events During Treatment of Drug-Resistant Tuberculosis: A Comparison Between Patients With or Without Human Immunodeficiency Virus Co-infection"],"prefix":"10.1007","volume":"36","author":[{"given":"Evans","family":"Sagwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunurai","family":"Ruswa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Paul","family":"Musasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aukje K.","family":"Mantel-Teeuwisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,6]]},"reference":[{"key":"91_CR1","volume-title":"National tuberculosis and leprosy programme: second medium term strategic plan for tuberculosis and leprosy, 2010\u20132015","author":"Ministry of Health and Social Services (MoHSS)","year":"2010","unstructured":"Ministry of Health and Social Services (MoHSS). National tuberculosis and leprosy programme: second medium term strategic plan for tuberculosis and leprosy, 2010\u20132015. Windhoek: MoHSS; 2010."},{"key":"91_CR2","volume-title":"2011\/12 estimates and projections of the impact of HIV and AIDS in Namibia","author":"Ministry of Health and Social Services (MoHSS)","year":"2012","unstructured":"Ministry of Health and Social Services (MoHSS). 2011\/12 estimates and projections of the impact of HIV and AIDS in Namibia. Windhoek: MoHSS; 2012."},{"key":"91_CR3","volume-title":"National tuberculosis and leprosy programme annual report: 2011\u20132012","author":"Ministry of Health and Social Services","year":"2012","unstructured":"Ministry of Health and Social Services. National tuberculosis and leprosy programme annual report: 2011\u20132012. MoHSS: Windhoek; 2012."},{"key":"91_CR4","unstructured":"World Health Organization (WHO). Treatment of tuberculosis. 4th ed. WHO\/HTM\/TB\/2009.420. Geneva: WHO; 2010."},{"key":"91_CR5","volume-title":"National guidelines for the management of tuberculosis","author":"Ministry of Health and Social Services (MoHSS)","year":"2006","unstructured":"Ministry of Health and Social Services (MoHSS). National guidelines for the management of tuberculosis. 2nd ed. Windhoek: MoHSS; 2006.","edition":"2"},{"key":"91_CR6","first-page":"1027","volume":"9","author":"E Nathanson","year":"2005","unstructured":"Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis. 2005;9:1027\u201333.","journal-title":"Int J Tuberc Lung Dis"},{"key":"91_CR7","first-page":"1373","volume":"9","author":"T T\u00f6r\u00fcn","year":"2005","unstructured":"T\u00f6r\u00fcn T, G\u00fcng\u00f6r G, \u00d6zmen I, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005;9:1373\u20137.","journal-title":"Int J Tuberc Lung Dis"},{"key":"91_CR8","first-page":"1314","volume":"11","author":"SS Shin","year":"2007","unstructured":"Shin SS, Pasechnikov AD, Gelmanova IY, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis. 2007;11:1314\u201320.","journal-title":"Int J Tuberc Lung Dis"},{"key":"91_CR9","first-page":"275","volume":"14","author":"E Bloss","year":"2010","unstructured":"Bloss E, Kuk\u0161a L, Holtz TH, et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000\u20132004. Int J Tuberc Lung Dis. 2010;14:275\u201381.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"9","key":"91_CR10","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.2165\/11591360-000000000-00000","volume":"71","author":"KK Venkatesh","year":"2011","unstructured":"Venkatesh KK, Swaminathan S, Andrews JR, et al. Tuberculosis and HIV co-infection: screening and treatment strategies. Drugs. 2011;71(9):1133\u201352.","journal-title":"Drugs"},{"issue":"7","key":"91_CR11","doi-asserted-by":"publisher","first-page":"e40781","DOI":"10.1371\/journal.pone.0040781","volume":"7","author":"P Isaakidis","year":"2012","unstructured":"Isaakidis P, Varghese B, Mansoor H, et al. Adverse events among HIV\/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. PLoS One. 2012;7(7):e40781. doi:10.1371\/journal.pone.0040781.","journal-title":"PLoS One"},{"issue":"5","key":"91_CR12","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1258\/ijsa.2008.008361","volume":"20","author":"DJB Marks","year":"2009","unstructured":"Marks DJB, Dheda K, Dawson R, et al. Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs. Int J STD AIDS. 2009;20(5):339\u201345.","journal-title":"Int J STD AIDS"},{"key":"91_CR13","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/1472-6963-9-169","volume":"9","author":"W Xu","year":"2009","unstructured":"Xu W, Lu W, Zhou Y, et al. Adherence to anti-tuberculosis treatment among pulmonary tuberculosis patients: a qualitative and quantitative study. BMC Health Serv Res. 2009;9:168.","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"91_CR14","doi-asserted-by":"publisher","first-page":"e19566","DOI":"10.1371\/journal.pone.0019566","volume":"6","author":"N Lorent","year":"2011","unstructured":"Lorent N, Sebatunzi O, Mukeshimana G, et al. Incidence and risk factors of serious adverse events during antituberculous treatment in Rwanda: a prospective cohort study. PLoS One. 2011;6(5):e19566. doi:10.1371\/journal.pone.0019566.","journal-title":"PLoS One"},{"issue":"1","key":"91_CR15","first-page":"6","volume":"5","author":"E Sagwa","year":"2012","unstructured":"Sagwa E, Mantel-Teeuwisse A, Ruswa N, et al. The burden of adverse events during treatment of drug-resistant tuberculosis in Namibia. South Med Rev. 2012;5(1):6\u201313.","journal-title":"South Med Rev"},{"key":"91_CR16","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","volume":"167","author":"D Yee","year":"2003","unstructured":"Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167:1472\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"91_CR17","doi-asserted-by":"crossref","unstructured":"Shakya R, Rao BS, Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann Pharmacother. 2004 Jun;38(6):1074-9.","DOI":"10.1345\/aph.1D525"},{"issue":"2","key":"91_CR18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1136\/thx.51.2.132","volume":"51","author":"JN Pande","year":"1996","unstructured":"Pande JN, Singh SPN, Khilnani GC, et al. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax. 1996;51(2):132\u20136.","journal-title":"Thorax"},{"key":"91_CR19","first-page":"51","volume":"1","author":"BL Nahar","year":"2006","unstructured":"Nahar BL, Mosharrof Hossain AKM, Islam MM, et al. A comparative study on the adverse effects of two anti-tuberculosis drugs regimen in initial two-month treatment period. Bangladesh J Pharmacol. 2006;1:51\u20137.","journal-title":"Bangladesh J Pharmacol"},{"key":"91_CR20","first-page":"648","volume":"5","author":"JJ Furin","year":"2001","unstructured":"Furin JJ, Mitnick CD, Shin SS, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2001;5:648\u201355.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"10","key":"91_CR21","first-page":"531","volume":"58","author":"AK Chhetri","year":"2008","unstructured":"Chhetri AK, Saha A, Verma SC, et al. A study of adverse drug reactions caused by first line anti-tubercular drugs in Directly Observed Treatment, Short Course (DOTS) therapy in western Nepal, Pokhara. J Pak Med Assoc. 2008;58(10):531\u20136.","journal-title":"J Pak Med Assoc"},{"issue":"1","key":"91_CR22","first-page":"51","volume":"21","author":"PV Kishore","year":"2008","unstructured":"Kishore PV, Subish P, Pradip O, et al. Pattern of adverse drug reactions experienced by tuberculosis patients in a tertiary care teaching hospital in western Nepal. Pak J Pharm Sci. 2008;21(1):51\u20136.","journal-title":"Pak J Pharm Sci"},{"issue":"3","key":"91_CR23","first-page":"134","volume":"4","author":"K Gholami","year":"2006","unstructured":"Gholami K, Kamali E, Hajiabdolbaghi M, et al. Evaluation of anti-tuberculosis induced adverse reactions in hospitalized patients. Pharm Pract. 2006;4(3):134\u20138.","journal-title":"Pharm Pract"},{"issue":"3","key":"91_CR24","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/j.1365-2125.2007.03034.x","volume":"65","author":"U Mehta","year":"2007","unstructured":"Mehta U, Durrheim DN, Blockman M, et al. Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV\/AIDS prevalence: prospective observational study. Br J Clin Pharmacol. 2007;65(3):396\u2013406.","journal-title":"Br J Clin Pharmacol"},{"key":"91_CR25","unstructured":"Sagwa E. Prevalence and risk factors of adverse events during treatment of drug resistant tuberculosis in a setting of high human immunodeficiency virus co-infection in Namibia: 2009-10. Unpublished Master of Public Health Thesis, Cape Town, South Africa; University of the Western Cape, Feb 2012."},{"key":"91_CR26","doi-asserted-by":"publisher","first-page":"e7186","DOI":"10.1371\/journal.pone.0007186","volume":"4","author":"KJ Seung","year":"2009","unstructured":"Seung KJ, Omatayo DB, Keshavjee S, et al. Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. Plos One. 2009;4:e7186. doi:10.1371\/journal.pone.0007186.","journal-title":"Plos One"},{"key":"91_CR27","first-page":"131","volume":"167","author":"T Papastavros","year":"2002","unstructured":"Papastavros T, Dolovich LR, Holbrook A, et al. Adverse events associated with pyrazinamide and levofloxacin in the treatment of multidrug-resistant tuberculosis. CMAJ. 2002;167:131\u20136.","journal-title":"CMAJ"},{"key":"91_CR28","first-page":"622","volume":"6","author":"P de Jager","year":"2002","unstructured":"de Jager P, van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis. 2002;6:622\u20137.","journal-title":"Int J Tuberc Lung Dis"},{"key":"91_CR29","doi-asserted-by":"publisher","unstructured":"Duggal P, Sarkar M. Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up. BMC Ear Nose Throat Disord. 2007;7:5. doi:10.1186\/1472-6815-7-5.","DOI":"10.1186\/1472-6815-7-5"},{"key":"91_CR30","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1128\/AAC.33.6.797","volume":"33","author":"RE Brummett","year":"1989","unstructured":"Brummett RE, Fox KE. Aminoglycoside-induced hearing loss in humans. Antimicrob Agents Chemother. 1989;33:797\u2013800.","journal-title":"Antimicrob Agents Chemother"},{"key":"91_CR31","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1056\/NEJM199310073291507","volume":"329","author":"JB Nadol","year":"1993","unstructured":"Nadol JB. Medical progress: hearing loss. N Engl J Med. 1993;329:1092\u2013102.","journal-title":"N Engl J Med"},{"key":"91_CR32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2174\/138161207779313731","volume":"13","author":"E Selimoglu","year":"2007","unstructured":"Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des. 2007;13:119\u201326.","journal-title":"Curr Pharm Des"},{"key":"91_CR33","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1093\/jac\/dkr221","volume":"66","author":"A Sturdy","year":"2011","unstructured":"Sturdy A, Goodman A, Jose RJ, et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother. 2011;66:1815\u201320.","journal-title":"J Antimicrob Chemother"},{"key":"91_CR34","doi-asserted-by":"publisher","first-page":"e352","DOI":"10.1371\/journal.pmed.0030352","volume":"3","author":"TE Tupasi","year":"2006","unstructured":"Tupasi TE, Gupta R, Quelapio MID, et al. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. Plos One. 2006;3:e352. doi:10.1371\/journal.pmed.0030352.","journal-title":"Plos One"},{"key":"91_CR35","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(00)02854-3","volume":"356","author":"A Carr","year":"2000","unstructured":"Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000;356:1423\u201330.","journal-title":"Lancet"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-013-0091-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-013-0091-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-013-0091-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-013-0091-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T17:03:40Z","timestamp":1659114220000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-013-0091-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,6]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["91"],"URL":"https:\/\/doi.org\/10.1007\/s40264-013-0091-1","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,6]]},"assertion":[{"value":"6 August 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}